October 14, 2021
The U.S. Food and Drug Administration’s (FDA) advisory panel recommended approving a half-dose booster of Moderna’s COVID-19 vaccine for older Americans, health care workers, and other high-risk groups.
The panel’s unanimous recommendation mirrors its guidance for those who received the Pfizer-BioNTech vaccine. The advisory panel said it had enough available data to support the safety and effectiveness of Moderna’s COVID-19 vaccine as a booster dose for the following groups at least six months after their two-dose series:
The meeting is the latest in a series from the nation’s infectious disease experts evaluating the safety, effectiveness, and need for booster doses of the available COVID-19 vaccines. The FDA’s discussion is just a part of the process. Experts from the Centers for Disease Control and Prevention also will discuss booster doses during meetings next week before a final recommendation is approved.
Here are five takeaways from today’s meeting:
HAP will continue to monitor public health developments and provide updates to members. Today’s meeting and presentations are available online.
Tomorrow’s FDA booster meeting about the Johnson & Johnson vaccine and mixing and matching vaccine brands also will be available to watch live.
Tags: Public Health | COVID-19
Click on topic below for category-specific news articles.
Support a healthier Pennsylvania.